Post by icemandios on Mar 21, 2023 19:04:55 GMT
Dear Stockholder:
NOTICE IS HEREBY GIVEN that the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) of Aspira Women’s Health Inc., a Delaware corporation (the “Company”), will be held on Tuesday, May 9, 2023 at 8:00 a.m. (Eastern Time). This year’s Annual Meeting will be conducted online via live webcast at www.virtualshareholdermeeting.com/AWH2023. You will not be able to attend the Annual Meeting in person.
The Annual Meeting will be held for the following purposes:
1. To elect as directors the six nominees named in the proxy statement and recommended by the Board of Directors to serve for a one-year term expiring at the 2024 annual meeting of stockholders and until their successors are elected and qualified (Proposal 1);
2. To hold an advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in the proxy statement (Proposal 2);
3. To hold an advisory vote on the frequency of future advisory votes to approve the compensation of the Company’s named executive officers (Proposal 3);
6. To ratify the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 (Proposal 6); and
NOTICE IS HEREBY GIVEN that the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) of Aspira Women’s Health Inc., a Delaware corporation (the “Company”), will be held on Tuesday, May 9, 2023 at 8:00 a.m. (Eastern Time). This year’s Annual Meeting will be conducted online via live webcast at www.virtualshareholdermeeting.com/AWH2023. You will not be able to attend the Annual Meeting in person.
The Annual Meeting will be held for the following purposes:
1. To elect as directors the six nominees named in the proxy statement and recommended by the Board of Directors to serve for a one-year term expiring at the 2024 annual meeting of stockholders and until their successors are elected and qualified (Proposal 1);
2. To hold an advisory vote to approve the compensation of the Company’s Named Executive Officers as disclosed in the proxy statement (Proposal 2);
3. To hold an advisory vote on the frequency of future advisory votes to approve the compensation of the Company’s named executive officers (Proposal 3);
4. To approve an amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan (the “2019 Plan”) (Proposal 4);
5. To approve a proposed amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock by a ratio of between one-for-ten and one-for-twenty (Proposal 5);
6. To ratify the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 (Proposal 6); and
7. To transact such other business as properly may be brought before the Annual Meeting or any adjournment or postponement thereof.
The foregoing items of business are more fully described in the proxy statement accompanying this Notice.